{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T11:25:02Z","timestamp":1761391502883},"reference-count":37,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,6,19]],"date-time":"2008-06-19T00:00:00Z","timestamp":1213833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2008,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A persistent high\u2010risk human papillomavirus (hrHPV) infection is a necessary condition for developing a cervical intraepithelial neoplasia and cervical cancer. The viral aetiology in cervical carcinogenesis has stimulated attempts to use HPV DNA detection in cervical cancer screening. In Finland there is an ongoing study assessing the benefits of primary HPV DNA testing in the setting of centrally organised mass screening for cervical cancer. Here we present the age\u2010specific prevalence of hrHPV infection and associated sociodemographic factors of 16,895 women aged 25\u201365 years attending the 5\u2010yearly cervical cancer screening between years 2003 and 2004. The overall hrHPV prevalence rate was 7.5%. The peak prevalence at the age group of 25\u201329 was 24.1% decreasing steadily thereafter to approximately 2.9% in women aged 65 years. Young age and marital status were the main determinants for oncogenic HPV types. Our study confirms the inverse relationship between age and hrHPV prevalence reported in many developed countries. As our prevalence rates and hence background risk for cervical cancer are not lower than in other European countries, it is likely that our lowest cervical cancer burden in Europe is due to health care actions justifying the organised cervical cancer screening. \u00a9 2008 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.23670","type":"journal-article","created":{"date-parts":[[2008,6,19]],"date-time":"2008-06-19T18:44:32Z","timestamp":1213901072000},"page":"1344-1349","source":"Crossref","is-referenced-by-count":23,"title":["Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland"],"prefix":"10.1002","volume":"123","author":[{"given":"Maarit","family":"Leinonen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Kotaniemi\u2010Talonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahti","family":"Anttila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadeusz","family":"Dyba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jussi","family":"Tarkkanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pekka","family":"Nieminen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,6,19]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990924)83:1<59::AID-IJC12>3.0.CO;2-N"},{"key":"e_1_2_6_3_2","volume-title":"Cancer incidence in Finland 2004 and 2005","author":"Finnish Cancer Registry","year":"2007"},{"key":"e_1_2_6_4_2","volume-title":"IARC Monographs on the evaluation of carcinogenic risks to humans","author":"International Agency for Research on Cancer","year":"2007"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.55.4.244"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602799"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22241"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67069-9"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.57.1.68"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.2178"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj209"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70731-8"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.OLQ.0000080177.82204.E0"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20076"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1845"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14955-0"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600918"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00311-7"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.12.002"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-6-252"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a114212"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-3242-6"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540500333566"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17354-6"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.05.117"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073204"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61450-0"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.07.005"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601650"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08151-5"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/509511"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e318064c8c5"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38663.459039.7C"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(97)80023-3"},{"key":"e_1_2_6_36_2","volume-title":"European guidelines for quality assurance in cervical cancer screening","author":"Arbyn M","year":"2008"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-6-27"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm079"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.23670","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.23670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T16:34:36Z","timestamp":1695918876000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.23670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,19]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,9,15]]}},"alternative-id":["10.1002\/ijc.23670"],"URL":"https:\/\/doi.org\/10.1002\/ijc.23670","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,19]]}}}